Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

Saved in:
Bibliographic Details
Published in:Leukemia 2020-09, Vol.34 (9), p.2473-2478
Main Authors: Locatelli, Franco, Whitlock, James A., Peters, Christina, Chen-Santel, Christiane, Chia, Victoria, Dennis, Robyn M., Heym, Kenneth M., Katz, Aaron J., Kelsh, Michael A., Sposto, Richard, Tu, Huakang, Tuglus, Catherine A., Verma, Anupam, Vinti, Luciana, Wilkes, Jennifer J., Zubarovskaja, Nathalya, Zugmaier, Gerhard, von Stackelberg, Arend, Sun, Weili
Format: Article
Language:English
Subjects:
692/699/1541/1990/283/2125
692/699/67
Acute lymphoblastic leukemia
Adolescent
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents - therapeutic use
Cancer Research
Child
Child, Preschool
Children
Critical Care Medicine
Female
Health aspects
Hematology
Humans
Intensive
Internal Medicine
Letter
Leukemia
Lymphatic leukemia
Lymphocytes B
Male
Medicine
Medicine & Public Health
Oncology
Pediatrics
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics
Recurrence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-020-0770-8